Back
Mirati Therapeutics 10K Form
Buy
51
MRTX
Mirati Therapeutics
Last Price:
51.83
Seasonality Move:
-5.31%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive MRTX News And Ratings
See the #1 stock for the next 7 days that we like better than MRTX
MRTX Financial Statistics
Sales & Book Value
| Annual Sales: | $72.09M |
|---|---|
| Cash Flow: | $-139.05M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $19.61 |
| Price / Book: | 2.64 |
Profitability
| EPS (TTM): | -13.39000 |
|---|---|
| Net Income (TTM): | $-739.61M |
| Gross Margin: | $409.68M |
| Return on Equity: | -61.93% |
| Return on Assets: | -54.02% |
Mirati Therapeutics Earnings Forecast
Key Mirati Therapeutics Financial Ratios
- The Gross Profit Margin over the past 12 years for MRTX is 568.29%.
- The Selling, General & Administrative Expenses for MRTX have been equal to 189.60% of Gross Profit Margin.
- The Research & Development expenses have been 705.49% of Revenue.
- The Interest Expense is -0.28% of Operating Income.
- The Net Earning history of MRTX is -807.99% of Total Revenues.
- Per Share Earnings over the last 19 years have been positive in 6 years.
Mirati Therapeutics Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Current Symbol: | MRTX |
| CUSIP: | 60468T |
| Website: | mirati.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 9.65 |
| Quick Ratio: | 9.47 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
MRTX Technical Analysis vs Fundamental Analysis
Buy
51
Mirati Therapeutics (MRTX)
is a Buy
Is Mirati Therapeutics a Buy or a Sell?
-
Mirati Therapeutics stock is rated a Buy
The current Mirati Therapeutics [MRTX] share price is $51.81. The Score for MRTX is 51, which is 2% above its historic median score of 50, and infers lower risk than normal.